Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | HTR1A | P08908 | 12/20 | 0.47 |
| ▸ | DRD2 | P14416 | 12/20 | 0.47 |
| ▸ | HTR2A | P28223 | 12/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.47 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360254 | 0.96 | KCNH2 (0.52) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5374851 | 0.87 | HTR1A (0.58) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5367834 | 0.87 | HRH3 (0.56) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5375161 | 0.86 | HRH3 (0.57) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5364675 | 0.86 | HRH3 (0.57) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5366085 | 0.86 | HRH3 (0.57) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5378501 | 0.84 | HTR1A (0.63) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5362989 | 0.83 | HRH3 (0.64) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5363296 | 0.83 | HRH3 (0.64) | KCNH2HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL1384500 | 0.83 | HRH3 (0.64) | KCNH2HTR1ADRD2HTR2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | claimed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | claimed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | DRD4, DRD2, DRD1 | KCNH2 3446/4885HTR1A 25/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.